Search results for "LUNG DEPOSITION"

showing 4 items of 4 documents

Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (F…

2018

Introduction: FRI is a novel computational fluid dynamics (CFD)-based technique using formulation profile and patients lung CT scan to simulate aerosol deposition. Aims and objectives: To evaluate lung deposition of pressurized metered dose inhaler (pMDI) extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G Trimbow®) with pMDI extrafine BDP/FF (Foster®) pMDI and compared them with reference gamma scintigraphy data. Methods: FRI was used to assess, in silico, the deposition of pMDI combination products (BDP/FF/G and BDP/FF) in 20 moderate to severe COPD patients. FRI combined high-resolution lung CT scans of each patient with in silico computational flow simulati…

DrugInhalationLung depositionmedicine.diagnostic_testmedicine.drug_classCopd patientsbusiness.industrymedia_common.quotation_subjectBeclometasone dipropionaterespiratory systemScintigraphy030226 pharmacology & pharmacyMetered-dose inhaler03 medical and health sciences0302 clinical medicine030228 respiratory systemmedicineCorticosteroidNuclear medicinebusinessmedia_commonmedicine.drugAirway pharmacology and treatment
researchProduct

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease U…

2021

Background: Functional respiratory imaging (FRI) is a computational fluid dynamics-based technique using three-dimensional models of human lungs and formulation profiles to simulate aerosol deposition. Methods: FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease (mean forced expiratory volume in 1 second 42% predicted) with in silico comput…

PathologyRespiratory SystemPharmaceutical ScienceINHALATION030226 pharmacology & pharmacyPulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesFormoterol FumaratePharmacology (medical)1102 Cardiorespiratory Medicine and Haematologycombination drugLungBRONCHODILATOROriginal Researchlung depositionBeclomethasonerespiratory systemDrug CombinationsTreatment OutcomeCorticosteroid1115 Pharmacology and Pharmaceutical SciencesPMDILife Sciences & BiomedicineCombination drugPulmonary and Respiratory Medicinemedicine.medical_specialtyLung depositionextrafinemedicine.drug_classIn silicoPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorioinhaled corticosteroid03 medical and health sciencespressurized metered-dose inhalerAdministration InhalationmedicineHumansIn patientComputer SimulationSMALL AIRWAYScombination drug extrafine functional respiratory imaging inhaled corticosteroid lung deposition pressurized metered-dose inhalerScience & TechnologyRespiratory imagingbusiness.industryDYSFUNCTION030228 respiratory systemASTHMAfunctional respiratory imagingbusiness
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Lung deposition of extrafine vs. non-extrafine tiple therapies in patients with COPD using Functional Respiratory Imaging (FRI)

2020

medicine.medical_specialtyCOPDLung depositionRespiratory imagingbusiness.industryInternal medicinemedicineCardiologyIn patientmedicine.diseasebusiness61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
researchProduct